Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether topical treatments (lactoperoxidase oral rinse / Biotene) changes relief of burning/discomfort (symptom relief; pain intensity) compared with placebo (very low certainty).
1 finding from 1 review
All‐cause mortality · participants with cirrhosis and with previous oesophagogastric variceal bleeding
It is very uncertain whether portosystemic shunts changes all‐cause mortality compared with endoscopic intervention with or without medical treatment (very low certainty).
1 finding from 1 review
All‐cause mortality · participants with cirrhosis and with previous oesophagogastric variceal bleeding
It is very uncertain whether transjugular intrahepatic portosystemic shunt changes all‐cause mortality compared with endoscopic intervention with or without medical treatment (very low certainty).
1 finding from 1 review
Rebleeding · participants with cirrhosis and with previous oesophagogastric variceal bleeding
It is very uncertain whether portosystemic shunts changes rebleeding compared with endoscopic intervention with or without medical treatment (very low certainty).
1 finding from 1 review
Rebleeding · participants with cirrhosis and with previous oesophagogastric variceal bleeding
It is very uncertain whether transjugular intrahepatic portosystemic shunt changes rebleeding compared with endoscopic intervention with or without medical treatment (very low certainty).
1 finding from 1 review
Health‐related quality of life · participants with cirrhosis and with previous oesophagogastric variceal bleeding
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality due to rebleeding · participants with cirrhosis and with previous oesophagogastric variceal bleeding
It is very uncertain whether transjugular intrahepatic portosystemic shunt changes mortality due to rebleeding compared with endoscopic intervention with or without medical treatment (very low certainty).
1 finding from 1 review
Acute hepatic encephalopathy · participants with cirrhosis and with previous oesophagogastric variceal bleeding
It is very uncertain whether transjugular intrahepatic portosystemic shunt changes acute hepatic encephalopathy compared with endoscopic intervention with or without medical treatment (very low certainty).
1 finding from 1 review
Chronic hepatic encephalopathy · participants with cirrhosis and with previous oesophagogastric variceal bleeding
It is very uncertain whether transjugular intrahepatic portosystemic shunt changes chronic hepatic encephalopathy compared with endoscopic intervention with or without medical treatment (very low certainty).
1 finding from 1 review
Health‐related quality of life · participants with cirrhosis and with previous oesophagogastric variceal bleeding
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality due to rebleeding · participants with cirrhosis and with previous oesophagogastric variceal bleeding
It is very uncertain whether portosystemic shunts changes mortality due to rebleeding compared with endoscopic intervention with or without medical treatment (very low certainty).
1 finding from 1 review
Acute hepatic encephalopathy · participants with cirrhosis and with previous oesophagogastric variceal bleeding
It is very uncertain whether portosystemic shunts changes acute hepatic encephalopathy compared with endoscopic intervention with or without medical treatment (very low certainty).
1 finding from 1 review
Chronic hepatic encephalopathy · participants with cirrhosis and with previous oesophagogastric variceal bleeding
It is very uncertain whether portosystemic shunts changes chronic hepatic encephalopathy compared with endoscopic intervention with or without medical treatment (very low certainty).
1 finding from 1 review
Blood loss: post‐treatment haematocrit (%) · early fetal death (less than 24 weeks)
1 finding from 1 review
Intervention not reported
In‐hospital death from any cause occurring within 4 weeks of randomization or the beginning of treatment · individuals with infant botulism
1 finding from 1 review
Serious adverse events or complications of treatment
It is very uncertain whether shock wave lithotripsy changes serious adverse events or complications of treatment compared with ureteroscopy with holmium laser or pneumatic lithotripsy (very low certainty).
1 finding from 1 review
Serious adverse events or complications of treatment
Shock wave lithotripsy may leads to lower serious adverse events or complications of treatment compared with mini‐percutaneous nephrolithotripsy (low certainty).
1 finding from 1 review
Serious adverse events or complications of treatments
It is very uncertain whether percutaneous nephrolithotripsy changes serious adverse events or complications of treatments compared with tubeless percutaneous nephrolithotripsy (very low certainty).
1 finding from 1 review
Serious adverse events or complications of treatment
It is very uncertain whether shock wave lithotripsy changes serious adverse events or complications of treatment compared with dissolution therapy (very low certainty).
1 finding from 1 review
Serious adverse events or complications of treatment — not reported
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found